{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:09:43Z","timestamp":1778764183554,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacl.2026.02.012","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:26:39Z","timestamp":1771979199000},"page":"947-960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3649-5335","authenticated-orcid":false,"given":"Hidenao","family":"Noritake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yonekura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tamakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Chida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacl.2026.02.012_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1016\/j.jacl.2026.02.012_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.jacl.2026.02.012_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jacl.2026.02.012_bib5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jacl.2026.02.012_bib6","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.jacl.2026.02.012_bib7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.012_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10238-022-00799-z","article-title":"Liver biopsy for assessment of chronic liver diseases: a synopsis","volume":"23","author":"Chowdhury","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jacl.2026.02.012_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3350\/cmh.2022.0329","article-title":"Non-alcoholic fatty liver disease: the pathologist's perspective","volume":"29","author":"Leow","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"10.1016\/j.jacl.2026.02.012_bib10","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jacl.2026.02.012_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jgh3.12289","article-title":"Discordant pathological diagnosis of non-alcoholic fatty liver disease: a prospective multicenter study","volume":"4","author":"Kuwashiro","year":"2020","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA Clinical Practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00330-024-11001-1","article-title":"Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis","volume":"35","author":"Azizi","year":"2025","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.012_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jacl.2026.02.012_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.jacl.2026.02.012_bib23","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2026.02.012_bib25","article-title":"Utility of pemafibrate in nonalcoholic steatohepatitis model mice induced by a choline-deficient, high-fat diet and dextran sulfate sodium","volume":"38","author":"Ota","year":"2024","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.13057","article-title":"Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: a single-arm prospective study","volume":"8","author":"Ono","year":"2024","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.jacl.2026.02.012_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib29","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.29437","article-title":"MR elastography: practical questions, from the AJR special series on imaging of fibrosis","volume":"222","author":"Yin","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","article-title":"Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat","volume":"137","author":"Braissant","year":"1996","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.jacl.2026.02.012_bib32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib33","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/HEP.0000000000000182","article-title":"Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines","volume":"78","author":"Gong","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jacl.2026.02.012_bib34","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/ATVBAHA.110.220525","article-title":"Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice","volume":"31","author":"Lalloyer","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib36","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib37","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib38","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jacl.2026.02.012_bib39","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jacl.2026.02.012_bib40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.cgh.2021.03.005","article-title":"Treatment candidacy for pharmacologic therapies for NASH","volume":"20","author":"Rowe","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.012_bib42","first-page":"544","article-title":"Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multi-level random effects model meta-analysis","volume":"82","author":"Taru","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib43","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.012_bib44","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.29437","article-title":"MR elastography: practical questions, from the AJR special series on imaging of fibrosis","volume":"222","author":"Yin","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.jacl.2026.02.012_bib45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.dld.2024.04.031","article-title":"Inflammation activity affects liver stiffness measurement by magnetic resonance elastography in MASLD","volume":"56","author":"Wei","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.012_bib46","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.012_bib47","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jacl.2026.02.012_bib48","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.16324","article-title":"Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"53","author":"Park","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.012_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.32151","article-title":"Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: a retrospective study","volume":"75","author":"Gidener","year":"2022","journal-title":"Hepatology"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:28:13Z","timestamp":1778761693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1933287426000498"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}